Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

NCT00121953 ↗

Phase 2/3 Withdrawn Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

RandomizedParallel-groupDouble-blindDiagnostic

Summary

The purpose of this study is to compare the effect of rosiglitazone versus placebo on soluble proinflammatory markers in peritoneal fluid of women with endometriosis.

Timeline

Start: 2005-07
Primary completion: 2008-05
Completion: 2008-05

Outcome

Outcome not reported

Stopped: “Due to the recent meta-analysis about CV adverse effects.”

Publications

Background Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004 Oct;82 Suppl 3:1008-13. doi: 10.1016/j.fertnstert.2004.02.148.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosiglitazone	Small molecule	4 mg	—